Further investigation of the 61 master hubs, especially those which are differentially expressed (C5AR1, CAVIN2, DCTN4, ETF1, GIMAP4-201, and NUDT21-201), may reveal novel therapeutic targets for psychiatric disorders, particularly depression, which represents the major portion of the clinical phenotype studied here. This evidence concerns the gene GIMAP4 and depressive symptom measurement.